Cyclic and Linear Peptides: What Cyclisation Changes

Cyclisation is one of the most consequential modifications available to a peptide chemist. It changes stability, selectivity and — often overlooked — how the compound has to be analysed.

How peptides are cyclised

Three routes are common. A disulfide bridge between two cysteine residues is the mildest and is reversible under reducing conditions. A lactam bridge between a side-chain amine and a side-chain carboxyl is covalent and not reversible in the same way. Head-to-tail cyclisation joins the N- and C-termini directly, eliminating both free ends.

Which route was used matters practically, because a disulfide-cyclised peptide can be opened by a reducing agent in your buffer while a lactam-bridged one cannot.

What it buys

Removing free termini removes the substrate for exopeptidases, so cyclic peptides are generally more stable. Constraining the backbone also reduces the conformational space the molecule can occupy, which frequently improves receptor selectivity: a constrained conformation may fit one receptor subtype well and another poorly. This is the basis of much of the selectivity engineering discussed in our note on melanocortin receptor subtypes.

What it costs analytically

Cyclic peptides complicate purity analysis in ways linear sequences do not.

The open-chain form has the same amino acid composition and nearly the same mass — differing by two hydrogens for a disulfide — so it can co-elute or elute very close to the target. Dimeric and oligomeric forms, where the bridge forms between two molecules rather than within one, are also possible and share the monomer’s composition entirely.

The consequence is that retention time alone is weak evidence of identity for a cyclic compound, and a purity percentage from a single chromatographic run may not resolve the isomers. Mass confirmation is the check that distinguishes them.

What to look for on a certificate

For any cyclic peptide, confirm that identity was established by mass and not by retention time alone, and check whether the analysis addressed oligomeric forms. Our notes on HPLC and mass spectrometry and why certificates disagree on purity cover the reasoning.

Storage

Avoid reducing agents in buffers used with disulfide-cyclised peptides, and minimise headspace oxygen for peptides containing free cysteine, where oxidation can form unintended bridges. General guidance is in storage and stability.

The chemistry of each route in more detail

Disulfide bridges

A disulfide forms by oxidation of two cysteine thiols. In synthesis this is usually done in dilute solution — high dilution suppresses intermolecular reaction and favours the intramolecular bridge — using air, DMSO or iodine as the oxidant. Peptides with more than one pair of cysteines require orthogonal protecting groups (Acm, Trt, Mmt and similar) removed in a controlled order, so that each bridge forms between the intended partners. Get the order wrong and the product is a disulfide isomer with the correct mass and the wrong three-dimensional structure — a failure mode that mass spectrometry alone will not catch.

Disulfides are redox-sensitive by nature. Dithiothreitol, TCEP, 2-mercaptoethanol and glutathione all reduce them. Any of these in a buffer will open the ring, and in a reducing intracellular environment the bridge may not survive. That is a real limitation, not a theoretical one, and it is the main reason a lactam is chosen when the constraint has to persist.

Lactam bridges

A lactam is an amide formed between a side-chain amine, typically lysine or ornithine, and a side-chain carboxyl, typically aspartate or glutamate. It is made on resin with orthogonal side-chain protection and a standard coupling reagent. The resulting bond is a normal amide: stable to reduction, stable across the usual pH range, and cleavable only by conditions that would degrade the peptide backbone anyway.

Bridge length is a design parameter. The i-to-i+4 spacing stabilises a single alpha-helical turn; i-to-i+7 spans two. Choosing the spacing is how a chemist decides which conformation to lock, and it is the reason two lactam analogs of the same parent sequence can have quite different receptor selectivity.

Head-to-tail cyclisation

Joining the N-terminal amine to the C-terminal carboxyl removes both free termini and produces a fully cyclic backbone. It is the most constraining option and the hardest to make: the reaction competes with cyclodimerisation and oligomerisation, so it is run at high dilution with a pseudo-proline or a turn-inducing residue to pre-organise the chain. Short sequences of five residues or fewer are notoriously difficult for geometric reasons.

Other routes worth knowing

• Thioether and stapled peptides. All-hydrocarbon staples installed by ring-closing metathesis between two alkene-bearing residues. Not reducible, and often improves membrane permeability as well as helicity.
• Side-chain-to-tail and tail-to-side-chain. One terminus joined to a side chain, leaving the other free for further modification.
• Click chemistry. A triazole formed between an azide and an alkyne, chemically inert and easy to install, though the triazole is a larger and more rigid linker than an amide.

Why constraint changes selectivity

A linear peptide in solution samples an enormous conformational ensemble, and only a small fraction of that ensemble matches the receptor-bound geometry. Binding therefore costs entropy: the peptide has to give up conformational freedom to adopt the bound state. Pre-organising the peptide into something close to the bound conformation pays part of that cost in advance, which raises affinity.

Selectivity follows from the same argument in reverse. A flexible peptide can adapt itself to several related receptors. A constrained one presents a fixed shape, which will fit the receptor it was designed against and fit related receptors less well. That is why cyclisation frequently improves selectivity and just as frequently reduces potency at the primary target — the locked conformation is rarely a perfect match on the first attempt, and it takes iteration to find a bridge position and length that improves both.

What cyclisation does to permeability

Cyclic peptides can be more membrane-permeable than their linear counterparts, but not automatically. The mechanism is intramolecular hydrogen bonding: a cyclic backbone can satisfy its own amide donors internally, reducing the polar surface exposed to solvent as it crosses a membrane. N-methylation of selected backbone amides reinforces this by removing donors outright. The effect is conformation-dependent and does not follow simply from being cyclic, which is why permeability has to be measured rather than assumed from the structure.

Analytical consequences in practice

The central analytical problem with any cyclisation is that it changes the molecular mass by a small, predictable amount — and several different outcomes share that same change.

• Disulfide formation removes two hydrogens: minus 2.016 Da. So does an unintended bridge between the wrong cysteine pair. So does an intermolecular bridge in a dimer, at exactly twice the mass.
• Lactam and head-to-tail formation lose a water molecule: minus 18.011 Da. So does an aspartimide side product, and so does a cyclodimer at twice the mass.

Mass alone therefore confirms that a cyclisation occurred, not that the intended one did. Distinguishing them takes orthogonal evidence:

• RP-HPLC retention. A correctly folded cyclic peptide is usually more compact and less hydrophobic on the surface, and typically elutes earlier than its linear precursor. Isomers separate on retention where they cannot on mass.
• Ellman’s assay. Quantifies free thiol. A fully oxidised disulfide peptide should show essentially none; residual free thiol means incomplete oxidation.
• Size-exclusion chromatography or native MS. Separates the intramolecular product from the cyclodimer, which HPLC alone may not resolve.
• Tandem MS after partial reduction. Selective reduction and alkylation followed by fragmentation maps which cysteines were actually paired — the definitive method for multi-bridge peptides.
• NMR or circular dichroism. CD gives a fast read on secondary structure; NOE-based NMR gives the actual constraint geometry where the question warrants it.

Reading a certificate for a cyclic peptide

A certificate written for a linear peptide does not answer the questions a cyclic one raises. What is worth looking for:

• The observed mass stated against the calculated mass for the cyclic form, with the water or hydrogen loss accounted for rather than left implicit.
• Which cyclisation chemistry was used, since that determines what the compound tolerates in a buffer.
• For multi-bridge peptides, evidence of correct connectivity — not only a mass.
• Purity by RP-HPLC with the gradient and column stated, since isomers co-elute under shallow gradients.
• Free-thiol content for disulfide peptides.
• Net peptide content, so that a concentration can be calculated from something other than vial weight.
• Counterion identity, since residual trifluoroacetate has its own activity in some cell assays.

On what a certificate can and cannot establish, and why two labs can report different purity for the same vial, see third-party versus in-house peptide testing.

Buffer and handling decisions that follow from the chemistry

• No reducing agents with disulfide-cyclised peptides. This includes DTT and TCEP added for unrelated reasons elsewhere in a protocol, and it includes freshly prepared buffers containing 2-mercaptoethanol.
• Minimise headspace oxygen for peptides with free cysteine, where slow air oxidation forms unintended bridges over weeks in storage.
• Watch pH. Disulfide exchange accelerates markedly above about pH 8; near-neutral or slightly acidic buffers are the safer default.
• Avoid metal contamination. Trace copper and iron catalyse thiol oxidation; a chelator in the buffer is cheap insurance.
• Aliquot on reconstitution. Repeated freeze–thaw cycles promote both aggregation and disulfide scrambling.
• Use low-binding plasticware for cationic or strongly hydrophobic cyclic peptides, where adsorption at low working concentrations is a real loss.

General storage guidance is in storage and stability of lyophilised peptides, and record-keeping in keeping a peptide inventory.

Naming and nomenclature

Cyclic peptides are written inconsistently across the literature. Square brackets around the bridged residues, a “cyclo(…)” prefix, an explicit “Cys1–Cys6 disulfide” note, or nothing at all. The same compound can appear under several conventions, and a literature search on one will miss the others. The nomenclature conventions worth knowing are collected in peptide nomenclature: analogs, fragments and salts.

Terms used here

• Disulfide bridge — covalent S–S bond between two cysteine side chains; reversible under reducing conditions.
• Lactam bridge — amide bond between a side-chain amine and a side-chain carboxyl; not reducible.
• Head-to-tail cyclisation — amide bond joining the N- and C-termini.
• Staple — hydrocarbon crosslink installed by ring-closing metathesis, typically to stabilise a helix.
• Disulfide isomer — correct mass, wrong cysteine pairing.
• Cyclodimer — two chains cyclised to each other rather than each to itself; twice the mass.
• Aspartimide — a cyclic side product at aspartate residues, also minus one water.
• Pre-organisation — restricting a molecule’s conformational freedom so that less entropy is lost on binding.

ExoLabz supplies compounds for laboratory research use only. Nothing on this page is medical advice or a suggestion of human or veterinary use. Certificates of analysis are published on this site.